Latest & Greatest

Latest & Greatest

Recent developments in the field of hematology/oncology, including drug approvals, policy updates, and clinical trial results

Dasatinib Granted Approval for Pediatric Indication

The FDA expanded the indication of dasatinib, a second-generation tyrosine kinase inhibitor, to include the treatment of pediatric patients (≥1 year of age) with...

Bristol-Myers Squibb to Purchase Celgene

Bristol-Myers Squibb (BMS) agreed to buy Celgene for $74 billion, making it the second-biggest purchase in the pharmaceutical and biotechnology industry and continuing a...

FDA Updates Guidance on Rare Disease Drug Development

The U.S. Food and Drug Administration (FDA) released a revised draft guidance for sponsors developing “orphan drugs” for the treatment or prevention of rare...

Congress Passes Bipartisan Sickle Cell Bill

The U.S. Congress recently passed the Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2018, bipartisan legislation...

Tagraxofusp-erzs Becomes First Approval for BPDCN

The U.S. Food and Drug Administration approved tagraxofusp-erzs for the treatment of adults and children (≥2 years of age) with blastic plasmacytoid dendritic cell...

FDA Approves Ravulizumab for PNH

The U.S. Food and Drug Administration (FDA) approved ravulizumab, a long-acting complement inhibitor that prevents hemolysis, for the treatment of adults with paroxysmal nocturnal...

FDA Approves Calaspargase Pegol-mknl for Acute Lymphocytic Leukemia

The FDA approved calaspargase pegol-mknl, an asparagine-specific enzyme, for the treatment of pediatric and young adult patients (ages 1 month to 21 years) with...

Cigna and Express Scripts Seal $54 Billion Merger

Health insurer Cigna completed its $54 billion acquisition of Express Scripts, which manages the prescription plans of more than 80 million Americans. The announcement...

FDA Expands Romiplostim Indication to Pediatric ITP

The U.S. Food and Drug Administration (FDA) approved romiplostim for the treatment of immune thrombocytopenia (ITP) in children younger than age 1 whose disease...

NCI Trims Operating Expenses for 2019

Despite receiving a larger budget for fiscal year 2019 – a $179-million increase over the previous year – the National Cancer Institute (NCI) plans...
Advertisement

Current Issue

March 2019, Volume 5, Issue 4

This issue features a look at the misconceptions about travel-associated blood clots, the treatment of young patients with myeloma, and more.